ClearArc Capital’s Novartis NVS Stock Holding History

ClearArc Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,656	Closed	-$359K	–	432
2015 Q4	$359K	Sell	4,656 -1,620	-26%	-$129K	0.08%	291
2015 Q3	$517K	Buy	6,276 +1,244	+25%	+$111K	0.11%	234
2015 Q2	$443K	Sell	5,032 -8,587	-63%	-$788K	0.08%	275
2015 Q1	$1.2M	Buy	13,619 +11,185	+460%	+$992K	0.25%	112
2014 Q4	$202K	Buy	+2,434	New	+$202K	0.04%	409

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Institutional Capital Chicago, Illinois $6.75B AUM 3.44% 1-Year Est. Return

ClearArc Capital's NVS Position: Q1 2016 in Review

ClearArc Capital sold out of Novartis (NVS) in Q1 2016, closing a stake of 4,656 shares — an estimated $359K sold.

ClearArc Capital first reported a position in NVS in Q4 2014 and held it in 5 quarters. The position peaked at $1.2M in Q1 2015. 875 funds tracked by Wall St. Rank hold NVS as of Q1 2016.

ClearArc Capital reported no remaining Novartis position as of Q1 2016 after selling out during the quarter.
ClearArc Capital sold 4,656 Novartis shares in Q1 2016, an estimated $359K.
ClearArc Capital first reported a position in Novartis in Q4 2014 and held it in 5 quarters.
ClearArc Capital's Novartis position peaked at $1.2M in Q1 2015.
875 funds tracked by Wall St. Rank held Novartis as of Q1 2016.

Based on ClearArc Capital's 13F filing for Q1 2016, filed 13 May 2016.